Pure Biologics S.A. (WSE:PUR)
Poland
· Delayed Price · Currency is PLN 4.240
+0.020 (0.47%)
At close: Dec 5, 2025
Pure Biologics Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | - | - | - | 0.66 | 0.25 | 0.57 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | 160.63% | -55.59% | -67.79% | Upgrade
|
| Cost of Revenue | 0.03 | 0.05 | 0.06 | 6.07 | 4.28 | 4.51 | Upgrade
|
| Gross Profit | -0.03 | -0.05 | -0.06 | -5.41 | -4.03 | -3.94 | Upgrade
|
| Selling, General & Admin | 15.07 | 14.92 | 18.26 | 28.71 | 20.69 | 20.46 | Upgrade
|
| Other Operating Expenses | -4.09 | -2.89 | -10.99 | -11.93 | -17.15 | -15.95 | Upgrade
|
| Operating Expenses | 11.25 | 12.34 | 7.48 | 19.28 | 6.46 | 7.62 | Upgrade
|
| Operating Income | -11.28 | -12.38 | -7.54 | -24.68 | -10.49 | -11.56 | Upgrade
|
| Interest Expense | -1.92 | -1.33 | -0.86 | -0.33 | -0.23 | -0.35 | Upgrade
|
| Interest & Investment Income | - | - | 0.28 | 0.2 | 0.09 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.52 | 0.52 | -0.41 | -0.02 | -0.06 | 0.12 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | - | -0 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -12.67 | -13.19 | -8.53 | -24.83 | -10.69 | -11.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.02 | -0.82 | -1.09 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.01 | 0.05 | 0.01 | - | Upgrade
|
| Other Unusual Items | - | - | -1.62 | - | - | - | Upgrade
|
| Pretax Income | -12.67 | -13.19 | -10.15 | -25.6 | -11.77 | -11.76 | Upgrade
|
| Earnings From Continuing Operations | -12.67 | -13.19 | -10.15 | -25.6 | -11.77 | -11.76 | Upgrade
|
| Earnings From Discontinued Operations | -5.26 | -6.25 | -25.55 | - | - | - | Upgrade
|
| Net Income | -17.93 | -19.44 | -35.69 | -25.6 | -11.77 | -11.76 | Upgrade
|
| Net Income to Common | -17.93 | -19.44 | -35.69 | -25.6 | -11.77 | -11.76 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 3 | 3 | 2 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 3 | 3 | 2 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 18.06% | 9.27% | 41.50% | 1.48% | 34.29% | 8.48% | Upgrade
|
| EPS (Basic) | -4.52 | -5.58 | -11.19 | -11.36 | -5.30 | -7.11 | Upgrade
|
| EPS (Diluted) | -4.52 | -5.58 | -11.19 | -11.36 | -5.30 | -7.11 | Upgrade
|
| Free Cash Flow | -5.12 | -10.83 | -23.44 | -23.15 | -24.71 | -1.91 | Upgrade
|
| Free Cash Flow Per Share | -1.29 | -3.11 | -7.35 | -10.27 | -11.12 | -1.16 | Upgrade
|
| Operating Margin | - | - | - | -3728.40% | -4129.13% | -2020.10% | Upgrade
|
| Profit Margin | - | - | - | -3867.52% | -4631.89% | -2055.24% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -3496.22% | -9727.56% | -334.62% | Upgrade
|
| EBITDA | -11.14 | -12.24 | -7.47 | -22.46 | -7.84 | -8.66 | Upgrade
|
| D&A For EBITDA | 0.14 | 0.14 | 0.07 | 2.23 | 2.65 | 2.9 | Upgrade
|
| EBIT | -11.28 | -12.38 | -7.54 | -24.68 | -10.49 | -11.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.